Analyst firms · Stephens · NEO
Stephens NEO price target and rating history
NeoGenomics Inc. (NEO) · Health Care
Stephens rates NeoGenomics Inc. (NEO) Overweight with a $18 price target, as of its latest action on Aug 21, 2023. It has published 4 rating actions on NEO since November 2021, including 1 upgrade and 1 downgrade.
- Current rating
- Overweight
- Price target
- $18
- Median target, all firms
- Too few
- Actions on NEO
- 4
Stephens price target on NEO
Every Stephens rating on NEO
- Aug 21, 2023
- Mar 29, 2022
- Jan 18, 2022
- Nov 5, 2021
How other firms rate NEO
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| BTIG | Buy | $28 | Oct 6, 2026 |
| Leerink Partners | Outperform | $25 | Apr 29, 2026 |
Questions about Stephens and NEO
- What is Stephens's price target for NEO?
- Stephens's latest stated price target for NeoGenomics Inc. (NEO) is $18, from its action on Aug 21, 2023.
- What is Stephens's rating on NEO?
- Stephens rates NEO Overweight, a bullish rating, as of Aug 21, 2023.
- When did Stephens last change its view on NEO?
- On Aug 21, 2023, Stephens upgrades to Overweight from Equal-Weight, price target $18.
More NEO rating histories
All Stephens ratingsNEO news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.